User login
This activity was written from interviews with the faculty.
Click Here to view the supplement.
- Faculty
- Topic Highlights
- Target Audience
- Educational Needs
- Learning Objectives
- Disclosure
- Accreditation
Faculty
Yehuda Handelsman, MD–Chair
Medical Director
Metabolic Institute of America
Tarzana, CA
Stuart Shankland, MD
Belding H. Scribner Endowed Chair of Medicine
Head, Division of Nephrology
University of Washington School of Medicine
Seattle, WA
Dace Trence, MD
Assistant Professor of Medicine
Director, Diabetes Care Center
University of Washington School of Medicine
Seattle, WA
Virginia Valentine, NP
Clinical Nurse Specialist, Diabetes
CEO, Diabetes Network
Albuquerque, NM
Topic Highlights
- Improving Screening and Diagnosis of Patients With Type 2 Diabetes Mellitus
- Managing Patients With Type 2 Diabetes Mellitus: Tight Control Reduces Complications
- Understanding Diabetic Kidney Disease: Current Insights
- Clinical Pearls and Questions From the Diabetes Educator’s Office
Target Audience
This educational activity is designed for endocrinologists, primary care physicians, nurses, diabetes educators, and other clinicians who treat patients with type 2 diabetes mellitus.
Educational Needs
The burden of type 2 diabetes mellitus (T2DM), in terms of morbidity, mortality, complications, and economic burden, is high and is predicted to rise even further. According to estimates from the US Centers for Disease Control and Prevention (CDC), between 7% and 8% of the population has T2DM, but this is projected to increase to 30% of the population within the next 30 years. The greatest increases are estimated to occur in African Americans and Hispanics, and in women (regardless of race or ethnicity). In addition, although diabetes screening has long been recommended for individuals beginning at around 50 years of age, this is no longer the case. Given the changing—and already altered—demographics of T2DM, clinicians should be monitoring for the disease in all patients over 30 years of age. Both microvascular (retinopathy, neuropathy, and nephropathy) and macrovascular (cardiovascular diseases) complications are consequences of less-than-optimal control of several important clinical parameters in patients with existing T2DM. Therefore, it is crucial that health care providers focus not only on good control of serum glucose but also on blood pressure and lipids as well. This supplement is designed to provide needed updates in the identifi cation and treatment of patients with T2DM, in order to reduce complications and the societal/medical burden of this disease.
Learning Objectives
By reading and studying this educational supplement, participants should be able to:
- Describe the potential for increased morbidity and accelerated mortality of suboptimally managed T2DM.
- List the risk factors for T2DM and discuss the recommendations for the screening and diagnosis of this disease.
- Discuss methods for identifying patients who may be at high risk for microvascular complications and explain the particular testing and treatment needs of patients who are at risk for renal impairment or failure.
- Critically review and, as necessary, revise existing strategies for building a multidisciplinary, collaborative approach to enhance communication among colleagues, educate patients, and improve treatment, as well as to locate and use quality assessment tools and guidelines.
- Demonstrate improved expertise in the management of patients with T2DM pharmacologic selection and explain the safety and efficacy profiles of antihyperglycemic agents when they are used in combination and/or with insulin.
Disclosure
Dr Handelsman has received grant/research support from Daiichi Sankyo, GlaxoSmithKline, Novartis, Novo Nordisk Inc., Takeda, sanofi - aventis, Tolerx, and XOMA. He has also received honoraria for being a consultant and/or serving on the speakers bureau for AstraZeneca, Bristol-Myers Squibb Company, Daiichi Sankyo, Gilead, Genentech, GlaxoSmithKline, Merck, Novartis, Takeda, Thetys, Tolerx, and XOMA.
Dr Handelsman is on the editorial advisory board of Clinical Endocrinology News.
Dr Trence has been a shareholder of Medtronic and sanofi -aventis.
Dr Shankland has no relevant financial relationships with any commercial interests.
Ms Valentine has received honoraria for being a consultant and/or serving on the speakers bureau and/or being a member of an advisory board for Amylin, Abbott Diabetes Care, Asante Solutions Inc., Boehringer Ingelheim, Calibra, Cequr, Dexcom, Intuity Medical, Eli Lilly and Company, Medtronic, F. Hoffman-La Roche Ltd., Pamlab, Takeda, and Tandem Pumps.
CHSE committee members have no relevant fi nancial relationships with any commercial interests: Carolyn Burns, MD; Dedra DeBerry, MA; Joyce Dunagan, MA, MSLS; Linda H. Freeman, DNS, RN; Terri Gipson, MSL; Ruth Greenberg, PhD; Lucy Juett, MS; Irene Litvan, MD; Loretta Maldaner; Mike Mansfi eld, DMD; Ashlee Melendez, RN, BSN; Lisa J. Pfi tzer, MD; Robert Sexton, MD; Uldis Streips, PhD; Kathy M. Vincent, MD; Lori Wagner, MD; Stephen Wheeler, MD; and Sharon Whitmer, EdD. CHSE offi ce staff members Jim Creg, Kim Moore, and Joyce Korfhage have no relevant relationships with any commercial interests.
Shirley Jones, Sylvia Reitman, and Michelle Rizzo with the Global Academy for Medical Education and medical writer Joanne Still have no relevant relationships with any commercial interests.
CME Reviewer: Ann Moore, MSN, RNC, FAANP, Professor of Nursing, Vanderbilt University School of Nursing, Nashville, TN, has no relevant relationships with any commercial interests.
RESOLUTION OF CONFLICT OF INTEREST
The CHSE has implemented a process to resolve conflict of interest for each CME activity. In order to help ensure content objectivity, independence and fair balance and to ensure that the content is aligned with the interest of the public, CHSE has resolved the conflict by external content review.
Unapproved/Off-Label Use Disclosure
CHSE requires CME faculty to disclose to the participants:
- When products or procedures being discussed are off-label, unlabeled, experimental, and or investigational (not US Food and Drug Administration [FDA] approved); and
- Any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.
Faculty may discuss information about pharmaceutical agents that are outside of FDA-approved labeling. This information is intended solely for CME and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
None of the authors discusses off-label uses of any FDA-approved drugs.
Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Louisville School of Medicine Continuing Health Sciences Education (CHSE) and Global Academy for Medical Education, LLC, an Elsevier business. CHSE is accredited by the ACCME to provide continuing education for physicians.
CHSE designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Term of Approval: February 1, 2011 – February 28, 2013.
Copyright (c) 2011 by Elsevier Inc.
This activity was written from interviews with the faculty.
Click Here to view the supplement.
- Faculty
- Topic Highlights
- Target Audience
- Educational Needs
- Learning Objectives
- Disclosure
- Accreditation
Faculty
Yehuda Handelsman, MD–Chair
Medical Director
Metabolic Institute of America
Tarzana, CA
Stuart Shankland, MD
Belding H. Scribner Endowed Chair of Medicine
Head, Division of Nephrology
University of Washington School of Medicine
Seattle, WA
Dace Trence, MD
Assistant Professor of Medicine
Director, Diabetes Care Center
University of Washington School of Medicine
Seattle, WA
Virginia Valentine, NP
Clinical Nurse Specialist, Diabetes
CEO, Diabetes Network
Albuquerque, NM
Topic Highlights
- Improving Screening and Diagnosis of Patients With Type 2 Diabetes Mellitus
- Managing Patients With Type 2 Diabetes Mellitus: Tight Control Reduces Complications
- Understanding Diabetic Kidney Disease: Current Insights
- Clinical Pearls and Questions From the Diabetes Educator’s Office
Target Audience
This educational activity is designed for endocrinologists, primary care physicians, nurses, diabetes educators, and other clinicians who treat patients with type 2 diabetes mellitus.
Educational Needs
The burden of type 2 diabetes mellitus (T2DM), in terms of morbidity, mortality, complications, and economic burden, is high and is predicted to rise even further. According to estimates from the US Centers for Disease Control and Prevention (CDC), between 7% and 8% of the population has T2DM, but this is projected to increase to 30% of the population within the next 30 years. The greatest increases are estimated to occur in African Americans and Hispanics, and in women (regardless of race or ethnicity). In addition, although diabetes screening has long been recommended for individuals beginning at around 50 years of age, this is no longer the case. Given the changing—and already altered—demographics of T2DM, clinicians should be monitoring for the disease in all patients over 30 years of age. Both microvascular (retinopathy, neuropathy, and nephropathy) and macrovascular (cardiovascular diseases) complications are consequences of less-than-optimal control of several important clinical parameters in patients with existing T2DM. Therefore, it is crucial that health care providers focus not only on good control of serum glucose but also on blood pressure and lipids as well. This supplement is designed to provide needed updates in the identifi cation and treatment of patients with T2DM, in order to reduce complications and the societal/medical burden of this disease.
Learning Objectives
By reading and studying this educational supplement, participants should be able to:
- Describe the potential for increased morbidity and accelerated mortality of suboptimally managed T2DM.
- List the risk factors for T2DM and discuss the recommendations for the screening and diagnosis of this disease.
- Discuss methods for identifying patients who may be at high risk for microvascular complications and explain the particular testing and treatment needs of patients who are at risk for renal impairment or failure.
- Critically review and, as necessary, revise existing strategies for building a multidisciplinary, collaborative approach to enhance communication among colleagues, educate patients, and improve treatment, as well as to locate and use quality assessment tools and guidelines.
- Demonstrate improved expertise in the management of patients with T2DM pharmacologic selection and explain the safety and efficacy profiles of antihyperglycemic agents when they are used in combination and/or with insulin.
Disclosure
Dr Handelsman has received grant/research support from Daiichi Sankyo, GlaxoSmithKline, Novartis, Novo Nordisk Inc., Takeda, sanofi - aventis, Tolerx, and XOMA. He has also received honoraria for being a consultant and/or serving on the speakers bureau for AstraZeneca, Bristol-Myers Squibb Company, Daiichi Sankyo, Gilead, Genentech, GlaxoSmithKline, Merck, Novartis, Takeda, Thetys, Tolerx, and XOMA.
Dr Handelsman is on the editorial advisory board of Clinical Endocrinology News.
Dr Trence has been a shareholder of Medtronic and sanofi -aventis.
Dr Shankland has no relevant financial relationships with any commercial interests.
Ms Valentine has received honoraria for being a consultant and/or serving on the speakers bureau and/or being a member of an advisory board for Amylin, Abbott Diabetes Care, Asante Solutions Inc., Boehringer Ingelheim, Calibra, Cequr, Dexcom, Intuity Medical, Eli Lilly and Company, Medtronic, F. Hoffman-La Roche Ltd., Pamlab, Takeda, and Tandem Pumps.
CHSE committee members have no relevant fi nancial relationships with any commercial interests: Carolyn Burns, MD; Dedra DeBerry, MA; Joyce Dunagan, MA, MSLS; Linda H. Freeman, DNS, RN; Terri Gipson, MSL; Ruth Greenberg, PhD; Lucy Juett, MS; Irene Litvan, MD; Loretta Maldaner; Mike Mansfi eld, DMD; Ashlee Melendez, RN, BSN; Lisa J. Pfi tzer, MD; Robert Sexton, MD; Uldis Streips, PhD; Kathy M. Vincent, MD; Lori Wagner, MD; Stephen Wheeler, MD; and Sharon Whitmer, EdD. CHSE offi ce staff members Jim Creg, Kim Moore, and Joyce Korfhage have no relevant relationships with any commercial interests.
Shirley Jones, Sylvia Reitman, and Michelle Rizzo with the Global Academy for Medical Education and medical writer Joanne Still have no relevant relationships with any commercial interests.
CME Reviewer: Ann Moore, MSN, RNC, FAANP, Professor of Nursing, Vanderbilt University School of Nursing, Nashville, TN, has no relevant relationships with any commercial interests.
RESOLUTION OF CONFLICT OF INTEREST
The CHSE has implemented a process to resolve conflict of interest for each CME activity. In order to help ensure content objectivity, independence and fair balance and to ensure that the content is aligned with the interest of the public, CHSE has resolved the conflict by external content review.
Unapproved/Off-Label Use Disclosure
CHSE requires CME faculty to disclose to the participants:
- When products or procedures being discussed are off-label, unlabeled, experimental, and or investigational (not US Food and Drug Administration [FDA] approved); and
- Any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.
Faculty may discuss information about pharmaceutical agents that are outside of FDA-approved labeling. This information is intended solely for CME and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
None of the authors discusses off-label uses of any FDA-approved drugs.
Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Louisville School of Medicine Continuing Health Sciences Education (CHSE) and Global Academy for Medical Education, LLC, an Elsevier business. CHSE is accredited by the ACCME to provide continuing education for physicians.
CHSE designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Term of Approval: February 1, 2011 – February 28, 2013.
Copyright (c) 2011 by Elsevier Inc.
This activity was written from interviews with the faculty.
Click Here to view the supplement.
- Faculty
- Topic Highlights
- Target Audience
- Educational Needs
- Learning Objectives
- Disclosure
- Accreditation
Faculty
Yehuda Handelsman, MD–Chair
Medical Director
Metabolic Institute of America
Tarzana, CA
Stuart Shankland, MD
Belding H. Scribner Endowed Chair of Medicine
Head, Division of Nephrology
University of Washington School of Medicine
Seattle, WA
Dace Trence, MD
Assistant Professor of Medicine
Director, Diabetes Care Center
University of Washington School of Medicine
Seattle, WA
Virginia Valentine, NP
Clinical Nurse Specialist, Diabetes
CEO, Diabetes Network
Albuquerque, NM
Topic Highlights
- Improving Screening and Diagnosis of Patients With Type 2 Diabetes Mellitus
- Managing Patients With Type 2 Diabetes Mellitus: Tight Control Reduces Complications
- Understanding Diabetic Kidney Disease: Current Insights
- Clinical Pearls and Questions From the Diabetes Educator’s Office
Target Audience
This educational activity is designed for endocrinologists, primary care physicians, nurses, diabetes educators, and other clinicians who treat patients with type 2 diabetes mellitus.
Educational Needs
The burden of type 2 diabetes mellitus (T2DM), in terms of morbidity, mortality, complications, and economic burden, is high and is predicted to rise even further. According to estimates from the US Centers for Disease Control and Prevention (CDC), between 7% and 8% of the population has T2DM, but this is projected to increase to 30% of the population within the next 30 years. The greatest increases are estimated to occur in African Americans and Hispanics, and in women (regardless of race or ethnicity). In addition, although diabetes screening has long been recommended for individuals beginning at around 50 years of age, this is no longer the case. Given the changing—and already altered—demographics of T2DM, clinicians should be monitoring for the disease in all patients over 30 years of age. Both microvascular (retinopathy, neuropathy, and nephropathy) and macrovascular (cardiovascular diseases) complications are consequences of less-than-optimal control of several important clinical parameters in patients with existing T2DM. Therefore, it is crucial that health care providers focus not only on good control of serum glucose but also on blood pressure and lipids as well. This supplement is designed to provide needed updates in the identifi cation and treatment of patients with T2DM, in order to reduce complications and the societal/medical burden of this disease.
Learning Objectives
By reading and studying this educational supplement, participants should be able to:
- Describe the potential for increased morbidity and accelerated mortality of suboptimally managed T2DM.
- List the risk factors for T2DM and discuss the recommendations for the screening and diagnosis of this disease.
- Discuss methods for identifying patients who may be at high risk for microvascular complications and explain the particular testing and treatment needs of patients who are at risk for renal impairment or failure.
- Critically review and, as necessary, revise existing strategies for building a multidisciplinary, collaborative approach to enhance communication among colleagues, educate patients, and improve treatment, as well as to locate and use quality assessment tools and guidelines.
- Demonstrate improved expertise in the management of patients with T2DM pharmacologic selection and explain the safety and efficacy profiles of antihyperglycemic agents when they are used in combination and/or with insulin.
Disclosure
Dr Handelsman has received grant/research support from Daiichi Sankyo, GlaxoSmithKline, Novartis, Novo Nordisk Inc., Takeda, sanofi - aventis, Tolerx, and XOMA. He has also received honoraria for being a consultant and/or serving on the speakers bureau for AstraZeneca, Bristol-Myers Squibb Company, Daiichi Sankyo, Gilead, Genentech, GlaxoSmithKline, Merck, Novartis, Takeda, Thetys, Tolerx, and XOMA.
Dr Handelsman is on the editorial advisory board of Clinical Endocrinology News.
Dr Trence has been a shareholder of Medtronic and sanofi -aventis.
Dr Shankland has no relevant financial relationships with any commercial interests.
Ms Valentine has received honoraria for being a consultant and/or serving on the speakers bureau and/or being a member of an advisory board for Amylin, Abbott Diabetes Care, Asante Solutions Inc., Boehringer Ingelheim, Calibra, Cequr, Dexcom, Intuity Medical, Eli Lilly and Company, Medtronic, F. Hoffman-La Roche Ltd., Pamlab, Takeda, and Tandem Pumps.
CHSE committee members have no relevant fi nancial relationships with any commercial interests: Carolyn Burns, MD; Dedra DeBerry, MA; Joyce Dunagan, MA, MSLS; Linda H. Freeman, DNS, RN; Terri Gipson, MSL; Ruth Greenberg, PhD; Lucy Juett, MS; Irene Litvan, MD; Loretta Maldaner; Mike Mansfi eld, DMD; Ashlee Melendez, RN, BSN; Lisa J. Pfi tzer, MD; Robert Sexton, MD; Uldis Streips, PhD; Kathy M. Vincent, MD; Lori Wagner, MD; Stephen Wheeler, MD; and Sharon Whitmer, EdD. CHSE offi ce staff members Jim Creg, Kim Moore, and Joyce Korfhage have no relevant relationships with any commercial interests.
Shirley Jones, Sylvia Reitman, and Michelle Rizzo with the Global Academy for Medical Education and medical writer Joanne Still have no relevant relationships with any commercial interests.
CME Reviewer: Ann Moore, MSN, RNC, FAANP, Professor of Nursing, Vanderbilt University School of Nursing, Nashville, TN, has no relevant relationships with any commercial interests.
RESOLUTION OF CONFLICT OF INTEREST
The CHSE has implemented a process to resolve conflict of interest for each CME activity. In order to help ensure content objectivity, independence and fair balance and to ensure that the content is aligned with the interest of the public, CHSE has resolved the conflict by external content review.
Unapproved/Off-Label Use Disclosure
CHSE requires CME faculty to disclose to the participants:
- When products or procedures being discussed are off-label, unlabeled, experimental, and or investigational (not US Food and Drug Administration [FDA] approved); and
- Any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.
Faculty may discuss information about pharmaceutical agents that are outside of FDA-approved labeling. This information is intended solely for CME and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
None of the authors discusses off-label uses of any FDA-approved drugs.
Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Louisville School of Medicine Continuing Health Sciences Education (CHSE) and Global Academy for Medical Education, LLC, an Elsevier business. CHSE is accredited by the ACCME to provide continuing education for physicians.
CHSE designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Term of Approval: February 1, 2011 – February 28, 2013.
Copyright (c) 2011 by Elsevier Inc.
